查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401897

到 2030 年液體活體組織切片市場預測：按產品和服務、樣本類型、技術、循環生物標記、癌症、臨床應用、最終用戶和地區進行的全球分析

Liquid Biopsy Market Forecasts to 2030 - Global Analysis By Product & Services, By Type of Sample, Technology, Circulating Biomarker, Cancer, Clinical Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC預測，2023年全球液體切片市場規模將達51億美元，預計2030年將達到188億美元，預測期內複合年成長率為20.3%。

液體活體組織切片是一種非侵入性醫學測試，可檢測血液和尿液等體液中的循環腫瘤 DNA (ctDNA)、RNA 和蛋白質等生物標記。液體活體組織切片透過識別與疾病相關的基因突變和變化來深入了解患者的健康狀況，特別是在癌症診斷中。液體活體組織切片提供了一種微創方法來監測和分析分子變化，以實現早期檢測、治療效果評估和個人化醫療。這種創新方法徹底改變了癌症診斷和監測，提供了個人健康狀況的動態、即時觀點。

根據國際癌症研究機構的數據，最常見的癌症類型是肺癌、乳癌、攝護腺癌和大腸。據估計，2020年至2040年，全球癌症患者人數將增加47%，2040年全球癌症患者人數將達2,840萬人。

全球癌症盛行率不斷上升

全球癌症發生率上升是液體切片市場的關鍵促進因素。隨著全球癌症發生率的增加，對有效、非侵入性診斷工具的需求日益成長。液體活體組織切片透過提供一種微創的癌症檢測和監測方法來滿足這一需求。液體活體組織切片可以實現早期檢測、客製化治療以及即時監測治療反應。此外，液體活體組織切片逐漸被認為是對抗癌症的寶貴工具，也是解決全球範圍內日益成長的癌症負擔的關鍵組成部分。

敏感性和特異性挑戰

這些測試在準確檢測或排除特定病理的表現參差不齊，引發了人們對其可靠性的擔憂。實現高靈敏度對於臨床效用至關重要。不一致的結果可能導致假陽性或假陰性，影響整體液體活體組織切片的準確性，從而阻礙整體市場的成長。

政府對衛生基礎建設的投資

增加的資金將加強研發並支持液體活體組織切片技術的技術進步和創新。基礎設施的改善將改善診斷服務的可近性，並促進液體切片檢查的引入以早期發現癌症。政府的支持也將促進液體切片檢查涵蓋主流醫療系統並使其廣泛使用。這與公共衛生配合措施一致，並為市場成長創造了有利的環境。

嚴格的監管要求以及與傳統切片檢查方法的競爭

嚴格的監管要求對液體切片檢查市場構成威脅，可能會延遲產品核准和市場進入。滿足這些監管要求需要大量的資源和時間。此外，市場還面臨來自成熟的傳統切片檢查方法的競爭，導致懷疑和採用緩慢。醫生和醫療機構可能更喜歡熟悉的傳統方法，這阻礙了液體活體組織切片技術的快速整合。

COVID-19 的影響：

COVID-19大流行對液體活體組織切片市場產生了重大影響。醫療保健系統和優先事項的中斷轉移了非必要診斷的注意力和資源，從而減緩了市場成長。然而，這場大流行凸顯了非侵入性和遠距離診斷的重要性，並激發了人們對液體活體組織切片技術的興趣。最大限度地減少患者接觸和加快診斷過程的需求加速了液體活體組織切片的採用，特別是在腫瘤學領域，並且它們對大流行帶來的醫療保健挑戰的潛在彈性和適應能力已得到證明。

預計在預測期內血液部分將是最大的

在預測期內，血液領域預計將主導液體活體組織切片市場並獲得最大的市場佔有率。這一優勢歸因於對非侵入性癌症診斷的需求不斷成長以及血液採樣的便利性。利用循環腫瘤 DNA (ctDNA) 和其他生物標記的血液液體活體組織切片有助於早期癌症檢測和治療監測。此外，次世代定序儀定序等高通量技術的進步提高了分子分析的精確度，進一步支持了該領域的成長。

前列腺癌細分市場預計在預測期內複合年成長率最高

在預測期內，前列腺癌領域的液體活體組織切片市場預計將出現無與倫比的成長。這種快速成長是由於對前列腺癌（通常無症狀）的準確和微創診斷解決方案的迫切需求所推動的。液體活體組織切片透過簡單的抽血檢測循環腫瘤 DNA (ctDNA) 和其他生物標記物，為前列腺癌的診斷和監測提供了革命性的方法。此外，液體活體組織切片技術的進步，加上對個人化醫療日益成長的興趣，使前列腺癌領域處於市場擴張的前沿。

佔有率最大的地區

預計在預測期內，北美將佔據液體活體組織切片市場的最大市場佔有率。這項優勢得益於完善的醫療基礎設施、加大的研發投入以及較高的癌症發生率等因素。此外，該地區還受益於先進醫療技術的早期採用和對個人化醫療的重視。此外，主要市場參與企業的存在和有利的政府配合措施使北美處於液體活體組織切片市場的前沿。

複合年成長率最高的地區：

亞太地區是預測期間液體切片市場複合年成長率最高的地區。原因包括癌症發生率上升、醫療基礎設施改善以及先進診斷技術的採用增加。該地區人口眾多且多樣化，加上政府加強衛生服務的配合措施，正在推動對非侵入性癌症診斷的需求。此外，國際和本地公司之間的合作以及對精準醫療日益成長的興趣進一步支持了亞太地區液體活體組織切片市場的擴張。

免費客製化服務

訂閱此報告的客戶可以利用以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與企業的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計/預測/複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 介紹
  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 最終用戶分析
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球液體活體組織切片市場：按產品和服務分類

  • 介紹
  • 套件和試劑
  • 平台及裝置
  • 服務

第6章全球液體切片市場：依樣本類型

  • 介紹
  • 血
  • 唾液
  • 尿
  • 其他類型樣品

第7章全球液體切片市場：依技術分類

  • 介紹
  • 使用 NGS 並行分析多個基因
  • 使用 PCR 微陣列進行單基因分析

第8章全球液體活體組織切片市場：透過循環生物標記

  • 介紹
  • 遊離 DNA (cfDNA)
  • 循環性腫瘤細胞
  • 循環腫瘤 DNA (ctDNA)
  • 細胞外囊泡（EVS）
  • 其他循環生物標記

第9章全球液體切片市場：依癌症分類

  • 介紹
  • 乳癌
  • 大腸直腸癌
  • 肝癌
  • 肺癌
  • 攝護腺癌
  • 其他癌症

第10章全球液體切片市場：依臨床應用

  • 介紹
  • 早期癌症篩檢
  • 復發監測
  • 治療方法選擇
  • 治療監測
  • 其他臨床應用

第11章全球液體活體組織切片市場：按最終用戶分類

  • 介紹
  • 門診手術中心
  • 診斷實驗室
  • 醫院和診所
  • 製藥和生物技術公司
  • 研究機構
  • 其他最終用戶

第10章全球液體切片市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司簡介

  • ANGLE plc
  • Biocept Inc.
  • Bio-Rad Laboratories
  • Epigenomics AG
  • F. Hoffmann-La Roche Ltd.
  • Freenome Holdings, Inc.
  • Guardant Health
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Johnson & Johnson
  • Laboratory Corporation of America Holdings
  • Lucence Health Inc.
  • MDxHealth SA
  • Myriad Genetics, Inc.
  • Oncimmune
  • QIAGEN NV
  • Thermo Fisher Scientific Inc
Product Code: SMRC24417

According to Stratistics MRC, the Global Liquid Biopsy Market is accounted for $5.1 billion in 2023 and is expected to reach $18.8 billion by 2030 growing at a CAGR of 20.3% during the forecast period. Liquid biopsy is a non-invasive medical test that detects biomarkers, such as circulating tumor DNA (ctDNA), RNA, and proteins, in bodily fluids like blood or urine. It provides insights into a patient's health, particularly in cancer diagnostics, by identifying genetic mutations or alterations associated with the disease. Liquid biopsy offers a less invasive method to monitor and analyze molecular changes, aiding in early detection, treatment response assessment, and personalized medicine. This innovative approach revolutionizes cancer diagnostics and monitoring, offering a dynamic and real-time perspective on an individual's health status.

According to the International Agency for Research on Cancer, the most prevalent types of cancer includes lungs cancer, breast cancer, prostate cancer, and colorectal cancer. The cancer cases across the globe is estimated to rise by 47% from 2020 to 2040, and the number of cancer cases are estimated to be 28.4 million by 2040 across the globe.

Market Dynamics:

Driver:

Increasing prevalence of cancer globally

The escalating global prevalence of cancer serves as a significant driver for the liquid biopsy market. As cancer incidence rises worldwide, there is a growing need for effective and non-invasive diagnostic tools. Liquid biopsies, offering a minimally invasive approach to detecting and monitoring cancers, meet this demand. They enable early detection, treatment customization, and real-time monitoring of therapeutic responses. Moreover, the increasing recognition of liquid biopsies as valuable tools in the fight against cancer positions them as a crucial component in addressing the rising burden of this disease on a global scale.

Restraint:

Sensitivity and specificity challenges

The variable performance of these tests in terms of accurately detecting and ruling out specific conditions raises concerns about their reliability. Achieving high sensitivity is crucial for clinical utility. Inconsistent results may lead to false positives or negatives, impacting the overall accuracy of liquid biopsy and thereby hindering overall market growth.

Opportunity:

Government investments on healthcare infrastructure

Increased funding enhances research and development, aiding technological advancements and innovation in liquid biopsy technologies. Improved infrastructure fosters better accessibility to diagnostic services, promoting the adoption of liquid biopsy for early cancer detection. Government support can also facilitate the integration of liquid biopsy into mainstream healthcare systems, ensuring widespread availability. This aligns with public health initiatives, creating a conducive environment for market growth.

Threat:

Stringent regulatory requirements and competition with traditional biopsy methods

Stringent regulatory requirements pose a threat to the liquid biopsy market by potentially slowing down product approvals and market entry. Meeting these requirements demands substantial resources and time. Additionally, the market faces competition from well-established traditional biopsy methods, leading to skepticism and slower adoption. Physicians and healthcare institutions may prefer conventional approaches they are familiar with, hindering the rapid integration of liquid biopsy techniques.

COVID-19 Impact:

The COVID-19 pandemic had a significant effect on the liquid biopsy market. Disruptions in healthcare systems and priorities diverted attention and resources away from non-essential diagnostics, slowing market growth. However, the pandemic underscored the importance of non-invasive and remote diagnostics, fueling interest in liquid biopsy technologies. The need for minimizing patient contact and expediting diagnostic processes accelerated the adoption of liquid biopsies, especially in oncology, demonstrating their potential resilience and adaptability in response to healthcare challenges posed by the pandemic.

The blood segment is expected to be the largest during the forecast period

Over the forecast period, the blood segment is poised to dominate the liquid biopsy market, securing the largest market share. This dominance is attributed to the escalating demand for non-invasive cancer diagnostics and the convenience of obtaining blood samples. Blood-based liquid biopsies, leveraging circulating tumor DNA (ctDNA) and other biomarkers, facilitate early cancer detection and treatment monitoring. Additionally, the segment's growth is further propelled by advancements in high-throughput technologies like next-generation sequencing, which enhance the precision of molecular analysis.

The prostate cancer segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the prostate cancer segment is expected to witness unparalleled growth in the liquid biopsy market. This surge is driven by the pressing need for accurate and minimally invasive diagnostic solutions for prostate cancer, a prevalent and often asymptomatic condition. Liquid biopsy's ability to detect circulating tumor DNA (ctDNA) and other biomarkers from a simple blood draw offers a revolutionary approach to prostate cancer diagnosis and monitoring. Moreover, advancements in liquid biopsy technologies, coupled with a growing emphasis on personalized medicine, position the prostate cancer segment at the forefront of the market's expansion.

Region with largest share:

North America is anticipated to command the largest market share during the forecast period in the liquid biopsy market. This dominance is attributed to factors such as a well-established healthcare infrastructure, increased investment in research and development, and a high prevalence of cancer. Moreover, the region benefits from the early adoption of advanced medical technologies and a strong emphasis on personalized medicine. Additionally, the presence of key market players, coupled with favorable government initiatives, positions North America at the forefront of the liquid biopsy market.

Region with highest CAGR:

The Asia Pacific region is positioned to experience the highest CAGR during the forecast period in the liquid biopsy market. Owing to the rising incidence of cancer, improving healthcare infrastructure, and increasing adoption of advanced diagnostic technologies. The region's large and diverse population, coupled with government initiatives to enhance healthcare services, fosters the demand for non-invasive cancer diagnostics. Additionally, collaborations between international and local companies, along with a growing focus on precision medicine, further drive the expansion of the liquid biopsy market in the Asia Pacific region.

Key players in the market:

Some of the key players in Liquid Biopsy Market include ANGLE plc, Biocept Inc., Bio-Rad Laboratories, Epigenomics AG, F. Hoffmann-La Roche Ltd., Freenome Holdings, Inc., Guardant Health, Inc., Illumina, Inc., Johnson & Johnson Laboratory Corporation of America Holdings, Lucence Health Inc., MDxHealth SA, Myriad Genetics, Inc., Oncimmune, QIAGEN N.V and Thermo Fisher Scientific Inc.

Key Developments:

In November 2023, ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, is delighted to announce the launch of its Portrait® PD-L1 test for the evaluation of PD-L1 protein expression on CTCs following extensive development and optimisation. The test is provided as a service from ANGLE's Onc-ADaPT® GCP-compliant laboratories and is conducted by an expert team with over 10 years' experience in CTC analysis.

In March 2023, ANGLE plc, a world-leading liquid biopsy company, is delighted to announce that its first bespoke assay development customer, Artios Pharma (Artios), has signed a new contract to utilise two DNA Damage Response assays developed by ANGLE in a Phase 1 clinical trial expected to commence short.

Product & Services Covered:

  • Kits & Reagents
  • Platforms & Instruments
  • Services

Type of Samples Covered:

  • Blood
  • Saliva
  • Urine
  • Other Types of Samples

Technologies Covered:

  • Multi-gene Parallel Analysis using NGS
  • Single-gene Analysis using PCR Microarrays

Circulating Biomarkers Covered:

  • Cell-free DNA (cfDNA)
  • Circulating Tumor Cells
  • Circulating Tumor DNA (ctDNA)
  • Extracellular Vesicles (EVS)
  • Other Circulating Biomarkers

Cancers Covered:

  • Breast Cancer
  • Colorectal Cancer
  • Liver Cancer
  • Lung Cancer
  • Prostate Cancer
  • Other Cancers

Clinical Applications Covered:

  • Early Cancer Screening
  • Recurrence Monitoring
  • Therapy Selection
  • Treatment Monitoring
  • Other Clinical Applications

End Users Covered:

  • Ambulatory Surgical Centers
  • Diagnostic Laboratories
  • Hospitals and Clinics
  • Pharmaceutical and Biotechnology Companies
  • Research Institutions
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Liquid Biopsy Market, By Product & Services

  • 5.1 Introduction
  • 5.2 Kits & Reagents
  • 5.3 Platforms & Instruments
  • 5.4 Services

6 Global Liquid Biopsy Market, By Type of Sample

  • 6.1 Introduction
  • 6.2 Blood
  • 6.3 Saliva
  • 6.4 Urine
  • 6.5 Other Types of Samples

7 Global Liquid Biopsy Market, By Technology

  • 7.1 Introduction
  • 7.2 Multi-gene Parallel Analysis using NGS
  • 7.3 Single-gene Analysis using PCR Microarrays

8 Global Liquid Biopsy Market, By Circulating Biomarker

  • 8.1 Introduction
  • 8.2 Cell-free DNA (cfDNA)
  • 8.3 Circulating Tumor Cells
  • 8.4 Circulating Tumor DNA (ctDNA)
  • 8.5 Extracellular Vesicles (EVS)
  • 8.6 Other Circulating Biomarkers

9 Global Liquid Biopsy Market, By Cancer

  • 9.1 Introduction
  • 9.2 Breast Cancer
  • 9.3 Colorectal Cancer
  • 9.4 Liver Cancer
  • 9.5 Lung Cancer
  • 9.6 Prostate Cancer
  • 9.7 Other Cancers

10 Global Liquid Biopsy Market, By Clinical Application

  • 10.1 Introduction
  • 10.2 Early Cancer Screening
  • 10.3 Recurrence Monitoring
  • 10.4 Therapy Selection
  • 10.5 Treatment Monitoring
  • 10.6 Other Clinical Applications

11 Global Liquid Biopsy Market, By End User

  • 11.1 Introduction
  • 11.2 Ambulatory Surgical Centers
  • 11.3 Diagnostic Laboratories
  • 11.4 Hospitals and Clinics
  • 11.5 Pharmaceutical and Biotechnology Companies
  • 11.6 Research Institutions
  • 11.7 Other End Users

10 Global Liquid Biopsy Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 ANGLE plc
  • 12.2 Biocept Inc.
  • 12.3 Bio-Rad Laboratories
  • 12.4 Epigenomics AG
  • 12.5 F. Hoffmann-La Roche Ltd.
  • 12.6 Freenome Holdings, Inc.
  • 12.7 Guardant Health
  • 12.8 Guardant Health, Inc.
  • 12.9 Illumina, Inc.
  • 12.10 Johnson & Johnson
  • 12.11 Laboratory Corporation of America Holdings
  • 12.12 Lucence Health Inc.
  • 12.13 MDxHealth SA
  • 12.14 Myriad Genetics, Inc.
  • 12.15 Oncimmune
  • 12.16 QIAGEN N.V
  • 12.17 Thermo Fisher Scientific Inc

List of Tables

  • Table 1 Global Liquid Biopsy Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Liquid Biopsy Market Outlook, By Product & Services (2021-2030) ($MN)
  • Table 3 Global Liquid Biopsy Market Outlook, By Kits & Reagents (2021-2030) ($MN)
  • Table 4 Global Liquid Biopsy Market Outlook, By Platforms & Instruments (2021-2030) ($MN)
  • Table 5 Global Liquid Biopsy Market Outlook, By Services (2021-2030) ($MN)
  • Table 6 Global Liquid Biopsy Market Outlook, By Type of Sample (2021-2030) ($MN)
  • Table 7 Global Liquid Biopsy Market Outlook, By Blood (2021-2030) ($MN)
  • Table 8 Global Liquid Biopsy Market Outlook, By Saliva (2021-2030) ($MN)
  • Table 9 Global Liquid Biopsy Market Outlook, By Urine (2021-2030) ($MN)
  • Table 10 Global Liquid Biopsy Market Outlook, By Other Types of Samples (2021-2030) ($MN)
  • Table 11 Global Liquid Biopsy Market Outlook, By Technology (2021-2030) ($MN)
  • Table 12 Global Liquid Biopsy Market Outlook, By Multi-gene Parallel Analysis using NGS (2021-2030) ($MN)
  • Table 13 Global Liquid Biopsy Market Outlook, By Single-gene Analysis using PCR Microarrays (2021-2030) ($MN)
  • Table 14 Global Liquid Biopsy Market Outlook, By Circulating Biomarker (2021-2030) ($MN)
  • Table 15 Global Liquid Biopsy Market Outlook, By Cell-free DNA (cfDNA) (2021-2030) ($MN)
  • Table 16 Global Liquid Biopsy Market Outlook, By Circulating Tumor Cells (2021-2030) ($MN)
  • Table 17 Global Liquid Biopsy Market Outlook, By Circulating Tumor DNA (ctDNA) (2021-2030) ($MN)
  • Table 18 Global Liquid Biopsy Market Outlook, By Extracellular Vesicles (EVS) (2021-2030) ($MN)
  • Table 19 Global Liquid Biopsy Market Outlook, By Other Circulating Biomarkers (2021-2030) ($MN)
  • Table 20 Global Liquid Biopsy Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 21 Global Liquid Biopsy Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 22 Global Liquid Biopsy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 23 Global Liquid Biopsy Market Outlook, By Liver Cancer (2021-2030) ($MN)
  • Table 24 Global Liquid Biopsy Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 25 Global Liquid Biopsy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 26 Global Liquid Biopsy Market Outlook, By Other Cancers (2021-2030) ($MN)
  • Table 27 Global Liquid Biopsy Market Outlook, By Clinical Application (2021-2030) ($MN)
  • Table 28 Global Liquid Biopsy Market Outlook, By Early Cancer Screening (2021-2030) ($MN)
  • Table 29 Global Liquid Biopsy Market Outlook, By Recurrence Monitoring (2021-2030) ($MN)
  • Table 30 Global Liquid Biopsy Market Outlook, By Therapy Selection (2021-2030) ($MN)
  • Table 31 Global Liquid Biopsy Market Outlook, By Treatment Monitoring (2021-2030) ($MN)
  • Table 32 Global Liquid Biopsy Market Outlook, By Other Clinical Applications (2021-2030) ($MN)
  • Table 33 Global Liquid Biopsy Market Outlook, By End User (2021-2030) ($MN)
  • Table 34 Global Liquid Biopsy Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 35 Global Liquid Biopsy Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 36 Global Liquid Biopsy Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
  • Table 37 Global Liquid Biopsy Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 38 Global Liquid Biopsy Market Outlook, By Research Institutions (2021-2030) ($MN)
  • Table 39 Global Liquid Biopsy Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.